Antibiotics versus biofilm: an emerging battleground in microbial communities

D Sharma, L Misba, AU Khan - Antimicrobial Resistance & Infection …, 2019 - Springer
Biofilm is a complex structure of microbiome having different bacterial colonies or single type
of cells in a group; adhere to the surface. These cells are embedded in extracellular …

Applying insights from biofilm biology to drug development—can a new approach be developed?

T Bjarnsholt, O Ciofu, S Molin, M Givskov… - Nature reviews Drug …, 2013 - nature.com
Most of the research on bacterial pathogenesis has focused on acute infections, but much
less is known about the pathogenesis of infections caused by bacteria that grow as …

Mycobacterium Biofilms

J Esteban, M García-Coca - Frontiers in microbiology, 2018 - frontiersin.org
The genus Mycobacterium includes human pathogens (Mycobacterium tuberculosis and
Mycobacterium leprae) and environmental organisms known as non-tuberculous …

The isoniazid paradigm of killing, resistance, and persistence in Mycobacterium tuberculosis

C Vilchèze, WR Jacobs Jr - Journal of molecular biology, 2019 - Elsevier
Isoniazid (INH) was the first synthesized drug that mediated bactericidal killing of the
bacterium Mycobacterium tuberculosis, a major clinical breakthrough. To this day, INH …

Rifamycin antibiotics and the mechanisms of their failure

RA Adams, G Leon, NM Miller, SP Reyes… - The Journal of …, 2021 - nature.com
Rifamycins are a class of antibiotics that were first discovered in 1957 and are known for
their use in treating tuberculosis (TB). Rifamycins exhibit bactericidal activity against many …

[HTML][HTML] The extracellular matrix of mycobacterial biofilms: could we shorten the treatment of mycobacterial infections?

P Chakraborty, A Kumar - Microbial cell, 2019 - ncbi.nlm.nih.gov
A number of non-tuberculous mycobacterium species are opportunistic pathogens and
ubiquitously form biofilms. These infections are often recalcitrant to treatment and require …

Chronic tonsillitis and biofilms: a brief overview of treatment modalities

M Abu Bakar, J McKimm, SZ Haque… - Journal of …, 2018 - Taylor & Francis
Recurrent tonsillitis is described as when an individual suffers from several attacks of
tonsillitis per year. Chronic and recurrent tonsillitis both cause repeated occurrences of …

Advances in key drug target identification and new drug development for tuberculosis

J Mi, W Gong, X Wu - BioMed Research International, 2022 - Wiley Online Library
Tuberculosis (TB) is a severe infectious disease worldwide. The increasing emergence of
drug‐resistant Mycobacterium tuberculosis (Mtb) has markedly hampered TB control …

Synthetic (p) ppGpp analogue is an inhibitor of stringent response in mycobacteria

K Syal, K Flentie, N Bhardwaj, K Maiti… - Antimicrobial agents …, 2017 - Am Soc Microbiol
Bacteria elicit an adaptive response against hostile conditions such as starvation and other
kinds of stresses. Their ability to survive such conditions depends, in part, on stringent …

The future for early-stage tuberculosis drug discovery

ES Zuniga, J Early, T Parish - Future microbiology, 2015 - Taylor & Francis
There is an urgent need for new and better drugs to treat tuberculosis due to lengthy and
complex treatment regimens and a rising problem of drug resistance. Drug discovery efforts …